Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Intermediate-risk non-muscle invasive bladder cancer (IR NMIBC)(Phase 2)
Achondroplasia (children)(Phase 2)
Catalysts
— Sep 2026
— Q1 2027
— 2027
Status note 'Dabogratinib 3x3' strategy: three Phase 2 trials (SURF303, SURF302, BEACH301) toward three potential registrational trials.
TYRA-430
Phase 1 · ActiveModality: small molecule (oral; FGFR4/FGFR3-biased)
Target FGFR4 / FGFR3
Indications
FGF19-positive hepatocellular carcinoma(Phase 1)
Status note SURF431 global Phase 1 open-label trial focused on clinical proof-of-concept in FGF19+ HCC.
TYRA-200
Phase 1 · ActiveModality: small molecule (oral; FGFR1/2/3 inhibitor)
Target FGFR1 / FGFR2 / FGFR3
Indications
FGFR2-driven intrahepatic cholangiocarcinoma resistant to prior FGFR inhibitors(Phase 1)
Status note SURF201 global Phase 1 open-label trial; designed active against acquired pan-FGFR inhibitor resistance mutations.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.